WorksheetsXXXXXXX
Total questions: 65
Worksheet time: 33mins
Name
Class
Date
1.
All antibody isotypes reduced
a)
Transient hypogammaglobulinemia of infancy
b)
X-linked Bruton's Tyrosine Kinase (BTK) Deficiency
c)
Selective IgA deficiency
d)
Common Variable Immunodeficiency (CVI)
e)
Isolated IgG Subclass Deficiency
2.
Reduced IgM and T cell defect
a)
Severe Combined Immunodeficiency (SCID)
b)
Peoside Phosphorylase (PNP) deficiency
c)
Wiskott-Aldrich Syndrome (WAS)
d)
DiGeorge Anomaly
e)
Ataxia-Tangiectasia
3.
Slow development of helper function in some patients
a)
Transient hypogammaglobulinemia of infancy
b)
X-linked Bruton's Tyrosine Kinase (BTK) Deficiency
c)
Selective IgA deficiency
d)
Common Variable Immunodeficiency (CVI)
e)
Isolated IgG Subclass Deficiency
4.
Ig class switching in B cells defect
a)
CD154 Deficiency
b)
Autoimmune Lymphoproliferative Syndrome (ALPS)
c)
CD25 deficiency
d)
Chediak-Higashi Syndrome
5.
Mutations in genes coding for caspase enzymes involved in apoptosis
a)
CD154 Deficiency
b)
Autoimmune Lymphoproliferative Syndrome (ALPS)
c)
CD25 deficiency
d)
Chediak-Higashi Syndrome
6.
Lack of T regulatory (Treg) cells which leads to lymphoproliferation and autoimmunity
a)
CD154 Deficiency
b)
Autoimmune Lymphoproliferative Syndrome (ALPS)
c)
CD25 deficiency
d)
Chediak-Higashi Syndrome
7.
IL-10
a)
Major inflammatory cytokines
b)
Major anti-inflammatory cytokines
8.
Binds to Fc of IgM and IgG
a)
C1q
b)
C1r
c)
C1s
d)
C4
e)
C2
9.
possible antibody mediated cytotoxicity
a)
Hyperacute
b)
Accelerated
c)
Acute
d)
Chronic
e)
Immunopathologic damage to the new organ
10.
Immune complex disorder Complex formation with soluble antigens
a)
Hyperacute
b)
Accelerated
c)
Acute
d)
Chronic
e)
Immunopathologic damage to the new organ
11.
Capable of fusing with APCs to facilitate antigen presentation
a)
Adjuvants
b)
Aluminum salts
c)
Oil in water emulsion
d)
Microparticle
12.
Stimulate the immune response by inducing release of chemokines and enhancing antigen uptake and migration of APCs
a)
Adjuvants
b)
Aluminum salts
c)
Oil in water emulsion
d)
Microparticle
13.
Preferentially stimulates Th2 responses
a)
Adjuvants
b)
Aluminum salts
c)
Oil in water emulsion
d)
Microparticle
14.
Which of the following classes is highest on lymphocytes and myeloid cells?
a)
MHC Class I
b)
MHC Class II
c)
MHC Class III
15.
Celiac disease (DQ2, DQ8)
a)
HLA B27
b)
HLA DR2, DR3
c)
HLA DR3, HLA DR4
d)
HLA DR4
e)
HLA B8
16.
Addison’s
a)
HLA B27
b)
HLA DR2, DR3
c)
HLA DR3, HLA DR4
d)
HLA DR4
e)
HLA B8
17.
Multiple sclerosis
a)
HLA B27
b)
HLA DR3
c)
HLA DR3, HLA DR4
d)
HLA DR4
e)
HLA B8
18.
T and B lymphocytes
a)
HLA Class I typing
b)
HLA Class II typing
c)
HLA Class III typing
d)
HLA Class IV typing
19.
What is the principle of HLA genotyping?
a)
ELISA
b)
IF
c)
Electrophoresis
d)
PCR
20.
Has secretory component
a)
IgG
b)
IgM
c)
IgA
d)
IgD
e)
IgE
21.
pentamer form of IgM is found in...
a)
serum
b)
plasma
c)
saliva
d)
surface of B cells
e)
surface of T cells
22.
Which of the following subclasses of IgA is found in secretions?
a)
IgA1
b)
IgA2
23.
▪ It is the site for antigen-dependent lymphopoiesis
a)
Primary Lymphoid Organs
b)
Secondary Lymphoid Organs
24.
Actively proliferate in the outer cortex under the influence of IL-7
a)
Double-negative thymocytes
b)
Double-positive thymocytes
25.
Positive or negative modulation of T and B cell receptor signaling
a)
CD4
b)
CD5
c)
CD8
d)
CD10
26.
B cells, follicular dendritic cells
a)
CD16
b)
CD19
c)
CD21
d)
CD23
27.
Adhesion molecule mediating homing peripheral lymphoid organs
a)
CD25
b)
CD44
c)
CD45R
d)
CD56
e)
CD94
28.
NK cells, subsets of T cells
a)
CD25
b)
CD44
c)
CD45R
d)
CD56
e)
CD94
29.
Essential in T and B cell antigen-stimulated activation
a)
CD25
b)
CD44
c)
CD45R
d)
CD56
e)
CD94
30.
It is associated with anaphylaxis, anti-inflammatory agent
a)
IgG
b)
IgM
c)
IgA
d)
IgD
e)
IgE
31.
Which of the following subclasses of IgA is found in serum?
a)
IgA1
b)
IgA2
32.
Cleaves C4 and C2
a)
C1q
b)
C1r
c)
C1s
d)
C4
e)
C2
33.
Part of C3 convertase
a)
C1q
b)
C1r
c)
C1s
d)
C4
e)
C2
34.
Binds to C4b – form C3 convertase
a)
C1q
b)
C1r
c)
C1s
d)
C4
e)
C2
35.
Cleaves C4 and C2
a)
MBL
b)
MASP-1
c)
MASP-2
36.
Dissociates C1r and C1s from C1q
a)
C1 inhibitor
b)
Factor I
c)
Factor H
d)
C4-binding protein
e)
S protein
37.
principal soluble regulator of alternative pathway
a)
C1 inhibitor
b)
Factor I
c)
Factor H
d)
C4-binding protein
e)
S protein
38.
Acts as a cofactor with I to inactivate C4b
a)
C1 inhibitor
b)
Factor I
c)
Factor H
d)
C4-binding protein
e)
S protein
39.
Prevents attachment of the C5b67 complex to cell membrane
a)
C1 inhibitor
b)
Factor I
c)
Factor H
d)
C4-binding protein
e)
S protein
40.
Prevents insertion of C9 into cell membrane
a)
DAF
b)
MIRL
c)
HRF
d)
CR1
e)
MCP
41.
Most efficient cofactor for Factor I-mediated cleavage of C3b It also helps to control the alternative pathway because binding of factor B to C3b is inhibited
a)
DAF
b)
MIRL
c)
HRF
d)
CR1
e)
MCP
42.
prevents formation of C3 convertase
a)
DAF
b)
MIRL
c)
HRF
d)
CR1
e)
MCP
43.
Inhibitor of MAC
a)
DAF
b)
MIRL
c)
HRF
d)
CR1
e)
MCP
44.
Lupuslike syndrome; recurrent infections
a)
C1 (q, r, or s)
b)
C2
c)
C3
d)
C4
e)
C5-C8
45.
Severe recurrent infections; glomerulonephritis
a)
C1 (q, r, or s)
b)
C2
c)
C3
d)
C4
e)
C5-C8
46.
Lupuslike syndrome
a)
C1 (q, r, or s)
b)
C2
c)
C3
d)
C4
e)
C5-C8
47.
Neisseria infections
a)
C1 (q, r, or s)
b)
C2
c)
C3
d)
C4
e)
C5-C8
48.
Hereditary angioedema
a)
C9
b)
C1NH
c)
DAF
d)
MIRL
49.
Pneumococcal diseases, sepsis, Neisseria infections
a)
Factor H or Factor I
b)
MBL
c)
Properdin
d)
MASP-2
50.
Pneumococcal diseases
a)
Factor H or Factor I
b)
MBL
c)
Properdin
d)
MASP-2
51.
Secreted by: Monocytes, macrophages, neutrophils, NK cells, activated T cells
a)
Interlekin-1β
b)
Tumor necrosis factor-α
c)
Interleukin-6
d)
Transforming growth factor-β
e)
Interferon-α, Interferon-β
52.
Secreted by: T cells, macrophages, other cell types
a)
Interlekin-1β
b)
Tumor necrosis factor-α
c)
Interleukin-6
d)
Transforming growth factor-β
e)
Interferon-α, Interferon-β
53.
Secreted by: Macrophages, DCs, virally infected cells
a)
Interlekin-1β
b)
Tumor necrosis factor-α
c)
Interleukin-6
d)
Transforming growth factor-β
e)
Interferon-α, Interferon-β
54.
Protect cells against viruses, increases class I MHC expression, activates NK cells
a)
Interlekin-1β
b)
Tumor necrosis factor-α
c)
Interleukin-6
d)
Transforming growth factor-β
e)
Interferon-α, Interferon-β
55.
Inhibition of both T and B cell proliferation, induction of IgA, inhibition of macrophages
a)
Interlekin-1β
b)
Tumor necrosis factor-α
c)
Interleukin-6
d)
Transforming growth factor-β
e)
Interferon-α, Interferon-β
56.
Which of the following cytokines is secreted by Th2 cells and mast cells?
a)
Interleukin-2
b)
Interleukin-4
c)
Interleukin-5
d)
Interleukin-10
e)
Interferon-γ
57.
Which of the following cytokines is secreted by Th2 cells, macrophages, and monocytes?
a)
Interleukin-2
b)
Interleukin-4
c)
Interleukin-5
d)
Interleukin-10
e)
Interferon-γ
58.
Growth and proliferation of T and B cells, NK cells activation and proliferation
a)
Interleukin-2
b)
Interleukin-4
c)
Interleukin-5
d)
Interleukin-10
e)
Interferon-γ
59.
Suppression of Th2 cells, inhibition of antigen presentation, inhibition of IFN-γ
a)
Interleukin-2
b)
Interleukin-4
c)
Interleukin-5
d)
Interleukin-10
e)
Interferon-γ
60.
Antibodymediated cytotoxic
a)
Type I Hypersensitivity
b)
Type II Hypersensitivity
c)
Type III Hypersensitivity
d)
Type IV Hypersensitivity
61.
Effector cells of this hypersensitivity include Host tissue cells
a)
Type I Hypersensitivity
b)
Type II Hypersensitivity
c)
Type III Hypersensitivity
d)
Type IV Hypersensitivity
62.
Immune mechanism of this hypersensitivity include releasing cytokines
a)
Type I Hypersensitivity
b)
Type II Hypersensitivity
c)
Type III Hypersensitivity
d)
Type IV Hypersensitivity
63.
Other autoimmune disorders
a)
Type I Hypersensitivity
b)
Type II Hypersensitivity
c)
Type III Hypersensitivity
d)
Type IV Hypersensitivity
64.
SLE
a)
Type I Hypersensitivity
b)
Type II Hypersensitivity
c)
Type III Hypersensitivity
d)
Type IV Hypersensitivity
65.
Myasthenia gravis
a)
Type I Hypersensitivity
b)
Type II Hypersensitivity
c)
Type III Hypersensitivity
d)
Type IV Hypersensitivity
100 %
